Cronos Group (CRON)
(Delayed Data from NSDQ)
$2.18 USD
+0.02 (0.93%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $2.19 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.18 USD
+0.02 (0.93%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $2.19 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Zacks News
Has CoDiagnostics, Inc. (CODX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CoDiagnostics, Inc. (CODX) and Cronos Group (CRON) have performed compared to their sector so far this year.
Ulta Beauty and Freshpet have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ulta Beauty and Freshpet have been highlighted as Zacks Bull and Bear of the Day
Ride The Cannabis Legalization Wave With These 3 Stocks
by Tirthankar Chakraborty
Stocks like Cronos Group (CRON), Canopy Growth (CGC) and Innovative Industrial Properties (IIPR) are sure to benefit at present amid the cannabis legalization wave.
Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cronos Group (CRON) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -28.57% and -13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 4th
by Zacks Equity Research
ARRY, CRON, ESTC, LEVL and TME have been added to the Zacks Rank #5 (Strong Sell) List on August 4, 2021.
Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cannabis Giant Tilray (TLRY) Skyrocketed Today
by Madeleine Johnson
Shares of Tilray (TLRY) closed sharply higher in Wednesday's trading session, gaining 25.8% after reporting mixed fourth-quarter earnings results.
New Strong Sell Stocks for July 16th
by Zacks Equity Research
JAZZ, MRNS, TWO, NCMI, and CRON have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2021
Markets Close Flat, Await New Jobs Data
by Mark Vickery
Tomorrow brings us our first steady diet of useful economic data of the week, with both normal Thursday Initial Jobless Claims and ADP (ADP) private-sector payrolls.
Cronos (CRON) Moves 15.2% Higher: Will This Strength Last?
by Zacks Equity Research
Cronos (CRON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cronos Group (CRON) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -50.00% and -25.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q1 Earnings on May 7: RDUS, CRON & OCGN
by Kinjel Shah
Let us take a look at three small biotech companies, RDUS, CRON and OCGN, which are gearing up for their earnings release.
New Strong Sell Stocks for May 3rd
by Zacks Equity Research
BIDU, CRON, FORM, LTC, and SUNW have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2021
Earnings Preview: Cronos Group (CRON) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Mar 1, 2021
by Zacks Equity Research
Companies in The News Are: CRON,PEG,SSP,BLDR
Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -216.67% and 23.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q4 results.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ
4 Stocks to Ride the Wave of Cannabis Legalization
by Nitish Marwah
Increasing tolerance, financial protection, credit availability, and legal votes have shaped America's hemp industry lately.
4 Stocks to Ride the Wave of Cannabis Legalization
by Nitish Marwah
Increasing tolerance, financial protection, credit availability, and legal votes have shaped America's hemp industry lately.
Should You Buy Cannabis Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.
Cronos Group (CRON) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 33.33% and 4.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Cannabis Stocks & ETFs Are Soaring
by Neena Mishra
Marijuana stocks are rising on hopes of favorable regulatory environment